Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)

Published on January 21, 2022

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.

Continue reading on website
Other news

5 areas where VCs can play an outsized role in addressing climate change

January 21, 2022
Jamil Wyne Contributor Jamil Wyne is an advisor, investor and author focusing on entrepreneurship, technology and economic development in emerging markets. He has worked with the World Bank, IFC, UN, Clean Energy Venture Group, Schmidt Futures, Ashoka, and other organizations. More posts by this contributor A close look at Singapore’s thriving startup ecosystem

Buy These 3 Bear Market Bargain Stocks

January 21, 2022
A stock is considered to enter bear market territory when it falls 20% or more from recent highs. There are plenty of stocks that fit this description in 2022, as...